A patient case demonstrating the efficacy of benralizumab in uncontrolled severe eosinophilic asthma refractory to omalizumab and mepolizumab treatment
Severe eosinophilic asthma is associated with a heavy burden and impact on daily living in patients experiencing uncontrolled symptoms, exacerbations, and treatment side effects. This case study reports a 49-year-old woman who presented to the severe asthma center with uncontrolled severe asthma des...
Guardado en:
Autores principales: | John Davison, Simon Doe |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/80eca5f3ece644f09867e137f705a203 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
New horizons for the treatment of severe, eosinophilic asthma: benralizumab, a novel precision biologic
por: Caminati M, et al.
Publicado: (2019) -
Development of Rheumatoid Arthritis During Anti-Interleukin-5 Therapy in a Patient with Refractory Chronic Eosinophilic Pneumonia
por: Kawabata H, et al.
Publicado: (2021) -
Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
por: Haldar P
Publicado: (2017) -
Real-Life Effectiveness of Mepolizumab on Forced Expiratory Flow between 25% and 75% of Forced Vital Capacity in Patients with Severe Eosinophilic Asthma
por: Angelantonio Maglio, et al.
Publicado: (2021) -
Mepolizumab for severe eosinophilic asthma – A one-year real life Portuguese study
por: R Brás, et al.
Publicado: (2021)